Oculus Issues Chinese Commercialization Plans For Microcyn Technology
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Oculus will formally begin commercializing its Microcyn technology-based Dermacyn products in China in cooperation with its Chinese partners China Bao Tai Investment and Sinopharm, the company announced May 5
You may also be interested in...
Pakistan Rolls Out The Carpet To Attract Global Clinical Trials
KARACHI - The Trade Development Authority of Pakistan will hold the country's first conference on clinical research April 26-27 in Karachi in an effort to better compete for global clinical trials with India and China, conference participants told PharmAsia News in a recent series of interviews
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
Need a specific report? 1000+ reports available
Buy Reports